Show simple item record

dc.contributor.authorElisaf, Moses S.en
dc.contributor.authorBairaktari, Eleni Then
dc.contributor.authorNikolaides, C.en
dc.contributor.authorKakaidi, B.en
dc.contributor.authorTzallas, C. S.en
dc.contributor.authorKatsaraki, A.en
dc.contributor.authorPavlidis, Nicholasen
dc.creatorElisaf, Moses S.en
dc.creatorBairaktari, Eleni Then
dc.creatorNikolaides, C.en
dc.creatorKakaidi, B.en
dc.creatorTzallas, C. S.en
dc.creatorKatsaraki, A.en
dc.creatorPavlidis, Nicholasen
dc.date.accessioned2018-06-22T09:52:57Z
dc.date.available2018-06-22T09:52:57Z
dc.date.issued2001
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41580
dc.description.abstractHormonal therapy plays a central role in the overall treatment of breast cancer. Aromatase inhibitors can inhibit the aromatase enzyme system resulting in a reduction of oestrogens. Letrozole is a non-steroidal aromatase inhibitor that effectively blocks aromatase activity without interfering with adrenal steroid biosynthesis. The drug can significantly reduce the levels of plasma oestrogens, which remain suppressed throughout the treatment. Data are scarce concerning the influence of these drugs on serum lipid levels. In the present study, we evaluated the effects of letrozole on the serum lipid profile in postmenopausal women with breast cancer. A total of 20 patients with breast cancer were treated with letrozole, 2.5 mg once daily. After an overnight fast, serum lipid parameters (total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, triglycerides, apolipoproteins A1, B and E and lipoprotein (a)) were measured before treatment and at 8 and 16 weeks afterwards. A significant increase in total cholesterol (P = 0.05), LDL cholesterol (P < 0.01) and apolipoprotein B levels (P = 0.05) in the serum, as well as in the atherogenic risk ratios total cholesterol/HDL cholesterol (P < 0.005) and LDL cholesterol/HDL cholesterol (P < 0.005) was noticed after letrozole treatment. We conclude that letrozole administration in postmenopausal women with breast cancer has an unfavourable effect on the serum lipid profile. © 2001 Elsevier Science Ltd. All rights reserved.en
dc.language.isoengen
dc.sourceEuropean journal of canceren
dc.subjectArticleen
dc.subjectAntineoplastic agentsen
dc.subjectHumanen
dc.subjectTamoxifenen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBreast neoplasmsen
dc.subjectControlled studyen
dc.subjectFemaleen
dc.subjectMiddle ageden
dc.subjectPriority journalen
dc.subjectClinical articleen
dc.subjectDrug effecten
dc.subjectRisk factorsen
dc.subjectBreast carcinomaen
dc.subjectRisk factoren
dc.subjectCholesterolen
dc.subjectLdlen
dc.subjectLow density lipoprotein cholesterolen
dc.subjectTriacylglycerolen
dc.subjectDrug activityen
dc.subjectHormonal therapyen
dc.subjectCholesterol blood levelen
dc.subjectHdlen
dc.subjectHigh density lipoprotein cholesterolen
dc.subjectLipid parametersen
dc.subjectLipoprotein blood levelen
dc.subjectLipoprotein(a)en
dc.subjectPostmenopauseen
dc.subjectApolipoprotein a-ien
dc.subjectApolipoprotein a1en
dc.subjectApolipoprotein ben
dc.subjectApolipoprotein een
dc.subjectApolipoproteins ben
dc.subjectApolipoproteins een
dc.subjectAromatase inhibitoren
dc.subjectDiet restrictionen
dc.subjectEnzyme inhibitorsen
dc.subjectHypercholesterolemiaen
dc.subjectLetrozoleen
dc.subjectLipiden
dc.subjectLipid blood levelen
dc.subjectLipidsen
dc.subjectNitrilesen
dc.subjectTriazolesen
dc.subjectTriglyceridesen
dc.titleEffect of letrozole on the lipid profile in postmenopausal women with breast canceren
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/S0959-8049(01)00155-1
dc.description.volume37
dc.description.issue12
dc.description.startingpage1510
dc.description.endingpage1513
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record